Alpha Tau Medical Ltd. (DRTS) News
Follow Alpha Tau Medical Ltd. (DRTS) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 4 public stories across 4 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Barclays maintains Alpha Tau Medical at Overweight, raises PT to $30
Barclays kept Alpha Tau Medical at Overweight and raised its price target to $30.00 per share from $17.00, according to Benzinga.
EQUITY | Sep 03, 2026, 01:33 PM UTC
L
Alpha Tau CFO Raphi Levy to participate in September investor conferences
Alpha Tau Medical said CFO Raphi Levy will participate in investor conferences in September, including the dates listed in the company announcement.
EQUITY | Sep 02, 2026, 12:07 PM UTC
L
DRTS Alpha Tau Medical - reports 100% objective response rate and 18.2-month median overall survival with Alpha dart plus pembrolizumab - No
DRTS Alpha Tau Medical - reports 100% objective response rate and 18.2-month median overall survival with Alpha dart plus pembrolizumab - No serious Alpha dart-associated adverse events; only two grade 1 events reported
EQUITY | Jul 21, 2026, 12:31 PM UTC
M
DRTS: Treats Glioblastoma Patient
Alpha Tau successfully treats first recurrent glioblastoma patient outside of the US with Alpha DaRT at Hadassah University Medical Center in Israel
EQUITY | Jun 23, 2026, 12:30 PM UTC